PURPOSE: To measure longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation (HSCT). PATIENTS AND METHODS: Body mass index (BMI) was analyzed in 179 survivors by category (underweight, healthy-weight, overweight, and obese) and by z score. Fat and lean body mass measured by dual-energy x-ray absorptiometry was analyzed as z scores. RESULTS: Over a median 6.6 years of follow-up, BMI z scores diminished significantly (0.32 pre-HSCT v -0.60 at 10 years post-HSCT; P < .001). Mean z scores for fat mass stayed within population norms, but those for lean mass remained below normal levels and diminished significantly over time (P = .018). Pre-HSCT BMI category and/or z score were strongly predictive of post-HSCT BMI (P < .001) and of fat and lean mass z scores (both P < .001). Survivors with extensive chronic graft-versus-host disease were more likely than others to have low BMI (P = .004) and low lean mass (P < .001) post-HSCT. Older age at HSCT (P = .015) and T-cell-depleted graft (P = .018) were predictive of lower post-HSCT BMI. Female patients had higher body fat (P = .002) and lower lean mass (P = .013) z scores than male patients, and black patients had higher fat mass z scores than white patients (P = .026). CONCLUSION: BMI declines significantly after allogeneic HSCT for childhood hematologic malignancies, reflecting primarily a substantial decrease in lean mass but not fat mass. Monitoring and preservation of BMI and lean mass are vital, especially in those with the identified risk factors.
PURPOSE: To measure longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation (HSCT). PATIENTS AND METHODS: Body mass index (BMI) was analyzed in 179 survivors by category (underweight, healthy-weight, overweight, and obese) and by z score. Fat and lean body mass measured by dual-energy x-ray absorptiometry was analyzed as z scores. RESULTS: Over a median 6.6 years of follow-up, BMI z scores diminished significantly (0.32 pre-HSCT v -0.60 at 10 years post-HSCT; P < .001). Mean z scores for fat mass stayed within population norms, but those for lean mass remained below normal levels and diminished significantly over time (P = .018). Pre-HSCT BMI category and/or z score were strongly predictive of post-HSCT BMI (P < .001) and of fat and lean mass z scores (both P < .001). Survivors with extensive chronic graft-versus-host disease were more likely than others to have low BMI (P = .004) and low lean mass (P < .001) post-HSCT. Older age at HSCT (P = .015) and T-cell-depleted graft (P = .018) were predictive of lower post-HSCT BMI. Female patients had higher body fat (P = .002) and lower lean mass (P = .013) z scores than male patients, and black patients had higher fat mass z scores than white patients (P = .026). CONCLUSION: BMI declines significantly after allogeneic HSCT for childhood hematologic malignancies, reflecting primarily a substantial decrease in lean mass but not fat mass. Monitoring and preservation of BMI and lean mass are vital, especially in those with the identified risk factors.
Authors: Bassem I Razzouk; Susan R Rose; Suradej Hongeng; Dana Wallace; Matthew P Smeltzer; Margie Zacher; Ching-Hon Pui; Melissa M Hudson Journal: J Clin Oncol Date: 2007-04-01 Impact factor: 44.544
Authors: A Cohen; T Duell; G Socié; M T van Lint; M Weiss; A Tichelli; A Rovelli; J F Apperley; P Ljungman; H J Kolb Journal: Bone Marrow Transplant Date: 1999-05 Impact factor: 5.483
Authors: W Chemaitilly; F Boulad; G Heller; N A Kernan; T N Small; R J O'Reilly; C A Sklar Journal: Bone Marrow Transplant Date: 2007-04-30 Impact factor: 5.483
Authors: Wing Leung; Hyunah Ahn; Susan R Rose; Sean Phipps; Teresa Smith; Kwan Gan; Madeline O'Connor; Gregory A Hale; Kimberly A Kasow; Raymond C Barfield; Renee M Madden; Ching-Hon Pui Journal: Medicine (Baltimore) Date: 2007-07 Impact factor: 1.889
Authors: Todd A Florin; G Edgar Fryer; Thomas Miyoshi; Michael Weitzman; Ann C Mertens; Melissa M Hudson; Charles A Sklar; Karen Emmons; Andrea Hinkle; John Whitton; Marilyn Stovall; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-07 Impact factor: 4.090
Authors: Danielle Novetsky Friedman; Patrick Hilden; Chaya S Moskowitz; Maya Suzuki; Farid Boulad; Nancy A Kernan; Suzanne L Wolden; Kevin C Oeffinger; Charles A Sklar Journal: Biol Blood Marrow Transplant Date: 2016-12-28 Impact factor: 5.742
Authors: Melissa M Hudson; Kevin C Oeffinger; Kendra Jones; Tara M Brinkman; Kevin R Krull; Daniel A Mulrooney; Ann Mertens; Sharon M Castellino; Jacqueline Casillas; James G Gurney; Paul C Nathan; Wendy Leisenring; Leslie L Robison; Kirsten K Ness Journal: J Clin Oncol Date: 2014-12-29 Impact factor: 44.544
Authors: Paul A Carpenter; Carrie L Kitko; Sharon Elad; Mary E D Flowers; Juan C Gea-Banacloche; Jörg P Halter; Flora Hoodin; Laura Johnston; Anita Lawitschka; George B McDonald; Anthony W Opipari; Bipin N Savani; Kirk R Schultz; Sean R Smith; Karen L Syrjala; Nathaniel Treister; Georgia B Vogelsang; Kirsten M Williams; Steven Z Pavletic; Paul J Martin; Stephanie J Lee; Daniel R Couriel Journal: Biol Blood Marrow Transplant Date: 2015-03-31 Impact factor: 5.742
Authors: F Bernard; P Auquier; I Herrmann; A Contet; M Poiree; F Demeocq; D Plantaz; C Galambrun; V Barlogis; J Berbis; F Garnier; N Sirvent; J Kanold; P Chastagner; H Chambost; G Michel Journal: Bone Marrow Transplant Date: 2014-02-17 Impact factor: 5.483
Authors: A Petryk; L E Polgreen; L Zhang; J S Hodges; D R Dengel; P A Hoffmeister; J Steinberger; K S Baker Journal: Bone Marrow Transplant Date: 2013-10-14 Impact factor: 5.483